Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Survival Data Boost Lilly & Novartis's CDK4/6 Assault On Pfizer's Ibrance In Metastatic Breast Cancer

By Alex Shimmings 18 Oct 2019

Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.

Topic cancer drug-development-landscape research

Medtech Insight: 世界の医療機器・医療技術の最新情報

Exact Sciences Buys Genomic Health In $2.8Bn Expansion Deal

06 Aug 2019

Cancer diagnostics company Exact Sciences is combining with Genomic Health in a major merger valued at $2.8bn. The combined company will offer two of the fastest growing brands in cancer diagnostics, Cologuard and Oncotype DX.

Topic cancer business-strategies

Medtech Insight: 世界の医療機器・医療技術の最新情報

UK Plan To Speed Access To ‘Cutting-Edge’ Products

By Ian Schofield 03 Jul 2019

Changes are being made to the UK’s Accelerated Access Collaborative to help streamline access to ground-breaking medicines and diagnostic tools in areas like dementia, diabetes and cancer.

Topic business-strategies cancer diabetes

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

02 Jul 2019

Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.

Topic cancer

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Imbruvica Replaces Chemo, Darzalex Boosts Standard Of Care In Front-Line CLL, Myeloma

02 Jul 2019

Late-breaker presentations at ASH showed that replacing chemotherapy agents with Imbruvica in CLL, and adding Darzalex to Revlimid and dexamethasone in multiple myeloma, is more effective than current standards of care in certain front-line settings.

Topic Cancer Drug approval

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Downward, Eastward or Inward? Blockbuster Film Puts Cancer Drug Prices In China Spotlight

02 Jul 2019

Bagging a $200m box office in its opening week in China, "Dying to Survive" is a sentimental movie about a Chinese businessman selling cancer drugs smuggled from India but unapproved in China that sees his life taking a drastic turn, from convicted felon to a Robin Hood-like hero as he helps those in need. The Chinese film authority’s clearance for the screening of the movie and the smash success signal three key messages about the future potential direction of oncology drugs in the country.

Topic cancer

Topic clinical-trials cancer

Topic cancer drug-development-landscape reimbursement